Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Inclusion Criteria: * Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) \> 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory * Last IV bisphosphonate treatment must be \>/= to 7 days and \</= to 30 days before the screening corrected serum calcium * Adults (\>/=18 years) * Adequate organ function as defined by the following criteria: * serum aspartate aminotransferase (AST) \</= 5 x upper limit of normal (ULN) * serum alanine aminotransferase (ALT) \</= 5 x upper limit of normal * serum total bilirubin \</= 2 x upper limit of normal Exclusion Criteria: * Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease * Receiving dialysis for renal failure * Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC * Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC * Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study * Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products) * Female subject is pregnant or br…